HK1256950A1 - 基因標籤在診斷上評估前列腺癌的治療策略的用途 - Google Patents

基因標籤在診斷上評估前列腺癌的治療策略的用途

Info

Publication number
HK1256950A1
HK1256950A1 HK18116088.9A HK18116088A HK1256950A1 HK 1256950 A1 HK1256950 A1 HK 1256950A1 HK 18116088 A HK18116088 A HK 18116088A HK 1256950 A1 HK1256950 A1 HK 1256950A1
Authority
HK
Hong Kong
Prior art keywords
diagnostically
prostate cancer
treatment strategies
genetic signature
evaluate treatment
Prior art date
Application number
HK18116088.9A
Other languages
English (en)
Inventor
Ashab Hussam Al-Deen
Nicholas Erho
Mohammed Alshalalfa
Elai Davicioni
Original Assignee
Decipher Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decipher Biosciences Inc filed Critical Decipher Biosciences Inc
Publication of HK1256950A1 publication Critical patent/HK1256950A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18116088.9A 2015-10-08 2018-12-14 基因標籤在診斷上評估前列腺癌的治療策略的用途 HK1256950A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239181P 2015-10-08 2015-10-08
PCT/CA2016/051180 WO2017059549A1 (en) 2015-10-08 2016-10-07 Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancer

Publications (1)

Publication Number Publication Date
HK1256950A1 true HK1256950A1 (zh) 2019-10-04

Family

ID=58487193

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116088.9A HK1256950A1 (zh) 2015-10-08 2018-12-14 基因標籤在診斷上評估前列腺癌的治療策略的用途

Country Status (7)

Country Link
US (1) US20180291459A1 (zh)
EP (1) EP3359689B1 (zh)
CN (1) CN108291262A (zh)
AU (1) AU2016334893B2 (zh)
CA (1) CA3000865A1 (zh)
HK (1) HK1256950A1 (zh)
WO (1) WO2017059549A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CA2881627A1 (en) 2012-08-16 2014-02-20 Genomedx Biosciences Inc. Cancer diagnostics using biomarkers
US11081225B2 (en) * 2015-03-30 2021-08-03 The Trustees Of The University Of Pennsylvania System and method for virtual radiation therapy quality assurance
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018201072A2 (en) 2017-04-28 2018-11-01 4D Path Inc. Apparatus, systems, and methods for rapid cancer detection
AU2018266733A1 (en) * 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
CN109111522B (zh) 2017-06-22 2022-02-01 北海康成(北京)医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
US11299786B2 (en) * 2018-07-05 2022-04-12 Rutgers, The State University Of New Jersey Gene panel to predict response to androgen deprivation in prostate cancer
CN109161597B (zh) * 2018-11-29 2019-03-22 上海晟燃生物科技有限公司 一种用于前列腺癌早期诊断的外泌体源性基因mRNA标志物组及其应用
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ, インコーポレイテッド 機械学習を使用するデータ圧縮および通信
CN111041094B (zh) * 2019-07-11 2022-03-08 江苏医药职业学院 检测tm2结构域蛋白2表达水平的试剂的应用和试剂盒
WO2022063957A1 (en) * 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3210515A1 (en) * 2021-02-01 2022-08-04 The Regents Of The University Of California Treatment of neuroendocrine cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
WO2013116742A1 (en) * 2012-02-01 2013-08-08 Mayo Foundation For Medical Education And Research Predicting responses to androgen deprivation therapy and methods for treating prostate cancer
CA2881627A1 (en) * 2012-08-16 2014-02-20 Genomedx Biosciences Inc. Cancer diagnostics using biomarkers

Also Published As

Publication number Publication date
AU2016334893B2 (en) 2022-11-17
CN108291262A (zh) 2018-07-17
EP3359689A1 (en) 2018-08-15
AU2016334893A1 (en) 2018-04-19
EP3359689A4 (en) 2019-05-22
EP3359689B1 (en) 2021-04-14
US20180291459A1 (en) 2018-10-11
WO2017059549A1 (en) 2017-04-13
CA3000865A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
HK1256950A1 (zh) 基因標籤在診斷上評估前列腺癌的治療策略的用途
IL288181A (en) Cancer treatment methods
IL259017A (en) Cancer cure is intended
ZA201702382B (en) Combination therapy for cancer
SG11201605585SA (en) Targeted therapy for small cell lung cancer
HK1231381A1 (zh) 癌症組合療法
SG11201701035SA (en) Cancer diagnosis and therapy
HK1251009B (zh) 用於治療癌症的治療組合物
IL246761A0 (en) Combined cancer treatment
HK1205254A1 (zh) 治療癌症的方法
GB201408297D0 (en) Treatment of cancer
GB201409363D0 (en) Skin cancer treatment
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
GB201407837D0 (en) Methods of cancer therapy
GB201417456D0 (en) Treatment of cancer
HK1200094A1 (zh) 免疫調節劑用於治療癌症的用途
GB201409362D0 (en) Treatment of cancer
GB201411884D0 (en) Cancer therapy
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201417819D0 (en) Agents for cancer therapy
GB201409457D0 (en) Molecules for cancer therapy
GB201406529D0 (en) Molecules for cancer therapy